Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter study of trabecular meshwork pigmentation after two years of treatment with TRAVATAN 0.004% ophthalmic solution
2009-011036-36Phase 4Terminated
- Sponsor
- Alcon Inc.
- Start
- Mar 2009
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of travoprost in open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by Alcon Inc. Primary endpoint: Trabecular meshwork pigmentation assessment. Started Mar 2009; status: terminated.
02
Drugs
travoprost
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on 2009-011036-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011036-36.